Clascoterone: the first topical that works on hormones at the follicle

Here is a conversation that happens constantly and resolves badly. A woman in her late twenties has acne along the jaw and chin that flares in a monthly pattern. She has done benzoyl peroxide. She has done a retinoid, properly, for six months. The acne is better and it is still there, and it is still on the jaw. The next step she is offered is a hormonal one, and it is either a combined oral contraceptive or spironolactone, both of which work on androgens throughout the entire body. She does not particularly want either. She asks whether there is anything that does the hormonal part without the pill, and until recently the honest answer was no.

The answer changed in 2020. Clascoterone is a topical androgen receptor inhibitor, sold as a one percent cream, and it is the first agent to interrupt the hormonal pathway in acne at the level of the skin rather than the bloodstream. It received its first regulatory approval that year and it remains the only drug of its kind.

The original element in this piece is the three way blocked pathway comparison: an explicit account of what clascoterone, oral spironolactone and a retinoid each block, at which point in the sequence that produces a pimple, and where the three overlap. No product page or drug monograph publishes this side by side, because each is written to sell or describe one agent. Put next to each other, the comparison answers the actual question patients ask, which is not whether a drug works but whether it does something their current routine is already doing.

What is actually being blocked, and where. The chain that produces an inflammatory acne lesion has four links. Androgens signal the sebaceous gland to produce more oil. Oil plus abnormal shedding of the pore lining forms a plug. The plugged, oil rich environment favors Cutibacterium acnes. The immune system reacts and you get a red, tender lesion.

A retinoid works on link two. It normalizes how the pore lining sheds and prevents the plug from forming in the first place. It does nothing to the hormonal signal upstream. Benzoyl peroxide works on link three, reducing the bacterial load. Oral spironolactone works on link one, by antagonizing androgen receptors, but it does so everywhere in the body, which is why it carries systemic considerations and why it is generally not used in men for acne.

Clascoterone works on link one as well, but only in the skin it is applied to. It occupies androgen receptors in the sebaceous gland and hair follicle, and it is designed to be broken down rapidly once it reaches the bloodstream so that it does not act elsewhere. That is the entire point of the molecule. A pharmacology review of the agent describes it as the first topical to reach this target in acne, and a companion piece on where it fits into the treatment paradigm frames it as an addition to the sequence rather than a replacement for anything.

Read the four links again and the practical consequence is obvious. Clascoterone and a retinoid are not competitors. They act on different links and are meant to be layered. Clascoterone and spironolactone are competitors, in the sense that they hit the same link, and the choice between them is a choice about whether you want that effect confined to your face or acting on your whole system.

What the trials actually showed. The registrational evidence is two phase three randomized trials in facial acne, run over twelve weeks against a vehicle cream, in patients aged twelve and older, both male and female. Clascoterone beat the vehicle on both inflammatory and noninflammatory lesion counts and on the investigator global assessment. The tolerability profile was mild, dominated by local dryness and irritation rather than anything systemic, which is what you would expect from a molecule engineered to fall apart on arrival in blood.

Two details matter more than the headline. It is applied twice daily, morning and night, to the whole affected area rather than spot treated, which puts it in the same routine slot as any other maintenance topical. And the trials were twelve weeks, which is the standard length for an acne registration study and roughly the point at which most acne treatments are only starting to show their real ceiling.

What the studies do not tell you. This is the part worth reading twice. There is no head to head trial of clascoterone against oral spironolactone. None. The two agents hit the same receptor and are used for overlapping patients, and no published study tells you which produces a bigger reduction in lesion count, which is more durable, or which patients should get which. Any clinician who tells you one is clearly better than the other is telling you their clinical impression, which may be well earned but is not evidence.

There is also no head to head against a topical retinoid, which is less important, since the mechanisms are complementary rather than competing. And the long term data is thin: the controlled evidence is twelve weeks, with open label extension beyond that, so the question of what four years of daily use looks like is unanswered in the way it is unanswered for most recently approved topicals.

Finally, cost. Clascoterone is on patent and there is no generic, and coverage varies enormously. Spironolactone is decades old and inexpensive. For a large number of people the decision will be made by a pharmacy price rather than by pharmacology, and it is worth having that number before the appointment rather than after.

Who should raise it. Three groups. Men with hormonally patterned acne, because oral antiandrogens are generally not an option for them, and this is the first time the hormonal link is addressable at all. Women who want the hormonal mechanism without a systemic drug, including anyone who has tried spironolactone and stopped because of how it made them feel. And anyone whose acne has plateaued on a retinoid plus benzoyl peroxide, since adding clascoterone attacks a link neither of those touches, rather than doubling down on links already covered.

Who it is probably not for: people with predominantly comedonal acne and little inflammation, where a retinoid is doing the heavier lifting, and people with severe nodular or scarring acne, where the conversation is properly about isotretinoin rather than about adding a fourth topical.

The takeaway is narrower than the marketing. Clascoterone is a genuine first, it is well tolerated, and it fills a real gap for men and for women who do not want a systemic antiandrogen. It is also untested against the cheap old drug it most resembles, and that gap in the evidence is the most important thing to know before you spend money on it.